Synovial Activation in Rheumatoid Arthritis

Immunogenomics and Human Disease

Volumn , Issue , 2006, Pages 299-325

  Huber, Lars C ^a   Gay, Renate E ^a   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cell cycle arrest; Cytokine independent targets; Functional genomics; Matrix degrading enzymes; Polyarticular disorder; Severe combined immunodeficiency (SCID); Synovial tissues; Toll like receptor

Indexed keywords

EID: 36048992271     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470034092.ch13     Document Type: Chapter

References (141)

1. Aderem A, Ulevitch RJ. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406(6797): 782-787.
2. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, Firestein GS. 1991. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 146(10): 3365-3371.
3. Asahara H, Fujisawa K, Kobata T, Hasunuma T, Maeda T, Asanuma M, Ogawa N, Inoue H, Sumida T, Nishioka, K. 1997. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthrit Rheum 40(5): 912-918.
4. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein, G. 2001. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 166(4): 2705-2711.
5. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, Hung GL, Glorioso JC, Robbins PD, Evans CH. 1993. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 90(22): 10764-10768.
6. Barchowsky A, Frleta D, Vincenti MP. 2000. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNFdependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 12(10): 1469-1479.
7. Baslund B, Tvede N, Danneskiold-Samsoe B, Peterson J, Peterson L, Schuurmann J. 2003. A novel human monoclonal antibody against IL-15 (humax-IL-15) in patients with active rheumatoid arthritis (RA): results of a double-blind, placebo-controlled phase I/II trial. Arthrit Rheum 48(9): S653.
8. Benbow U, Brinckerhoff CE. 1997. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 15(8-9): 519-526.
9. Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC, Breedveld FC, Hack CE, Sturk A. 2002. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthrit Rheum 46(11): 2857-2866.
10. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. 2002. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 6(3): 357-376.
11. Bohne S, Sletten K, Menard R, Buhling F, Vockler S, Wrenger E, Roessner A, Rocken C. 2004. Cleavage of AL amyloid proteins and AL amyloid deposits by cathepsins B, K, and L. J Pathol 203(1): 528-537.
12. Borish LC, Steinke JW. 2003. 2. Cytokines and chemokines. J Allergy Clin Immunol 111 (2 suppl): S460-475.
13. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2(8657): 244-247.
14. Brentano F, Schorr O, Simmen B, Gay R, Michel BA, Gay S, Kyburz D. 2004. TLR expression profiles of RA synovial fibroblasts compared to OA and normal skin fibroblasts. Arthrit Rheum (Abstract) 50(9): S517.
15. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. 1999. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145(3): 527-538.
16. Bush KA, Farmer KM, Walker JS, Kirkham BW. 2002. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthrit Rheum 46(3): 802-805.
17. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. 2002. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 61(10): 934-936.
18. Caulfield JP, Hein A, Dynesius-Trentham R, Trentham DE. 1982. Morphologic demonstration of two stages in the development of type II collagen-induced arthritis. Lab Invest 46(3):321-343.
19. Chabaud M, Page G, Miossec P. 2001. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 167(10): 6015-6020.
20. Cheson BD. 2002. CHOP plus rituximab-balancing facts and opinion. New Engl J Med 346(4): 280-282.
21. Chiocchia G, Boissier MC, Fournier C. 1991. Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur J Immunol 21(12): 2899-2905.
22. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthrit Rheum 46(12): 3143-3150.
23. Collette J, Ulku AS, Der CJ, Jones A, Erickson AH. 2004. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer 112(2): 190-199.
24. Dayer JM. 2003. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42(suppl 2): ii3-10.
25. Dayer JM, Beutler B, Cerami A. 1985. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162(6): 2163-2168.
26. Dike LE, Farmer SR. 1988. Cell adhesion induces expression of growth-associated genes in suspension-arrested fibroblasts. Proc Natl Acad Sci USA 85(18): 6792-6796.
27. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, Jr, O'Connor JV. 1986. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163(6): 1433-1450.
28. Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF, 3rd, Gay RE, Michel BA, Fontana A, Gay S, Pisetsky DS, Distler, O. 2005. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 102(8): 2892-2897.
29. Dooley S, Herlitzka I, Hanselmann R, Ermis A, Henn W, Remberger K, Hopf T, Welter C. 1996. Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann Rheum Dis 55(5): 298-304.
30. Ermann J, Fathman CG. 2001. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2(9): 759-761.
31. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM. 1996. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7(10): 1261-1280.
32. Fassbender HG. 1983. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res 3(2): 141-155.
33. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Rev Immunol 14: 397-440.
34. Firestein GS. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthrit Rheum 39(11): 1781-1790.
35. Fox DA. 1997. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthrit Rheum 40(4): 598-609.
36. Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, Pap T, Gay RE, Fontana A, Gay S. 1998a. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4{thorn} T lymphocytes in rheumatoid arthritis. Eur J Immunol 28(9): 2661-2671.
37. Franz JK, Pap T, Muller-Ladner U, Gay R, Burmester G, Gay S. 1998b. T-cell independent joint destruction. In T Cells in Arthritis Miossec P, van-den BW, Firestein GS (eds). Basel: Birkenha üser; 55-74.
38. Franz JK, Pap T, Hummel KM, Nawrath M, Aicher WK, Shigeyama Y, Muller-Ladner U, Gay RE, Gay S. 2000. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthrit Rheum 43(3): 599-607.
39. Furst D. 2004. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26(12): 1960-1975.
40. Gabriel SE. 2001. The epidemiology of rheumatoid arthritis. Rheum Dis Clin N Am 27(2): 269-281.
41. Geiler T, Kriegsmann J, Keyszer GM, Gay RE, Gay S. 1994. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice. Arthrit Rheum 37(11): 1664-1671.
42. Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, Schmitt E, Rude E. 1995. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 92(11): 4823-4827.
43. Goldschmidt TJ, Jansson L, Holmdahl R. 1990. In vivo elimination of T cells expressing specific T-cell receptor V beta chains in mice susceptible to collagen-induced arthritis. Immunology 69(4): 508-514.
44. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104(10): 1393-1401.
45. Gravallese EM. 2002. Bone destruction in arthritis. Ann Rheum Dis 61(suppl 2): ii84-86.
46. Grimbacher B, Aicher WK, Peter HH, Eibel H. 1997. Measurement of transcription factor c-fos and EGR-1 mRNA transcription levels in synovial tissue by quantitative RT-PCR. Rheumatol Int 17(3): 109-112.
47. Guinec N, Dalet-Fumeron V, Pagano M. 1993. 'In vitro' study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler 374(12): 1135-1146.
48. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB. 2004. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 279(3): 1615-1620.
49. Han Z, Boyle DL, Manning AM, Firestein GS. 1998. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28(4): 197-208.
50. Harris WH, Sledge CB. 1990. Total hip and total knee replacement (1). New Engl J Med 323(11): 725-731.
51. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. 1991. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21(10): 2575-2579.
52. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. 1993. Development of TH1 CD4{thorn}T cells through IL-12 produced by Listeria-induced macrophages. Science 260(5107): 547-549.
53. Huet G, Flipo RM, Colin C, Janin A, Hemon B, Collyn-d'Hooghe M, Lafyatis R, Duquesnoy B, Degand P. 1993. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthrit Rheum 36(6): 772-780.
54. Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, Bromme D, Gay S. 1998. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 25(10): 1887-1894.
55. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, Tindal MH, Robbins PD, Evans CH. 1994. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1(1): 64-69.
56. Ishikawa H, Hirata S, Andoh Y, Kubo H, Nakagawa N, Nishibayashi Y, Mizuno K. 1996. An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Rheumatol Int 16(2): 53-60.
57. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthrit Rheum 39(5): 797-809.
58. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, Distler, O. 2004. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthrit Rheum 50(5): 1468-1476.
59. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. 1995. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 95(6): 2868-2876.
60. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Engl J Med 345(15): 1098-1104.
61. Kehlen A, Thiele K, Riemann D, Langner J. 2002. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 127(3): 539-546.
62. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. 1999. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 90(1): 65-78.
63. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. 1992. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52(13): 3610-3614.
64. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. 1993. Effects of membraneassociated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178(1): 55-62.
65. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM. 1992. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90(3): 772-779.
66. Kontny E, Ziolkowska M, Dudzinka E, Filipowicz-Sosnowska A, Ryzewska A. 1995. Modified expression of c-Fos and c-Jun proteins and production of interleukin-1 beta in patients with rheumatoid arthritis. Clin Exp Rheumatol 13(1): 51-57.
67. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9): 1345-1352.
68. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, Hart BA, Breedveld FC, Tak PP. 1998. Asymptomatic synovitis precedes clinically manifest arthritis. Arthrit Rheum 41(8): 1481-1488.
69. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Engl J Med 349(20): 1907-1915.
70. Kriegsmann J, Keyszer GM, Geiler T, Brauer R, Gay RE, Gay S. 1995. Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 72(2): 209-214.
71. Kuchen S, Seemayer CA, Kuenzler P, Pap T, Gay R, Michel BA, Neidhart M, Gay S. 2001. Cytokineindependent up-regulation of matrix metalloproteinase 1 mRNA expression by the stress activated protein kinase 4. Arthrit Rheum 44(abstract): S183.
72. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. 1989. Anchorageindependent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 83(4): 1267-1276.
73. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS. 2004. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23(27): 4681-4689.
74. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthrit Rheum 41(5): 778-799.
75. Lee ZH, Kim HH. 2003. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305(2): 211-214.
76. Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, Flipo RM. 1997. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol 36(7): 735-743.
77. Li WQ, Dehnade F, Zafarullah M. 2001. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166(5): 3491-3498.
78. Liew FY, McInnes IB. 2002. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61(suppl 2): ii100-102.
79. Maini RN, Elliott MJ, Brennan FM, Feldmann M. 1995. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 101(2): 207-212.
80. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194): 1932-1939.
81. Makarov SS. 2001. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthrit Res 3(4): 200-206.
82. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177(4): 1199-1204.
83. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. 2002. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthrit Rheum 46(2): 507-513.
84. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA. 1996. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthrit Rheum 39(4): 583-591.
85. McInnes IB, Gracie JA. 2004. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmac 4(4): 392-397.
86. McInnes IB, Gracie JA, Harnett M, Harnett W, Liew FY. 2003. New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis 62(suppl 2): ii51-54.
87. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. 2000. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthrit Rheum 43(4): 801-811.
88. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA. 1997. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gammadependent and-independent mechanisms. Eur J Immunol 27(8): 1958-1965.
89. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, Makarov SS. 1998. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95(23): 13859-13864.
90. Mishiro T, Nakano S, Takahara S, Miki M, Nakamura Y, Yasuoka S, Nikawa T, Yasui N. 2004. Relationship between cathepsin B and thrombin in rheumatoid arthritis. J Rheumatol 31(7): 1265-1273.
91. Muller-Ladner U, Kriegsmann J, Gay RE, Koopman WJ, Gay S, Chatham WW. 1995a. Progressive joint destruction in a human immunodeficiency virus-infected patient with rheumatoid arthritis. Arthrit Rheum 38(9): 1328-1332.
92. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S. 1996. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149(5): 1607-1615.
93. Nakano K, Okada Y, Saito K, Tanaka Y. 2004. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthrit Rheum 50(8): 2450-2458.
94. Neidhart M, Rethage J, Kuchen S, Kunzler P, Crowl RM, Billingham ME, Gay RE, Gay S. 2000. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthrit Rheum 43(12): 2634-2647.
95. Neidhart M, Jungel A, Comazzi M, Von Knoch R, Ospelt C, Simmen B, Michel BA, Gay R, Gay S. 2004. Deficient expression of interleukin-10 receptor alpha-chain in RA synovium-limitations of inflammatory animal models. Arthrit Rheum (abstract) 50(9): S112.
96. Neumann E, Judex M, Kullmann F, Grifka J, Robbins PD, Pap T, Gay RE, Evans CH, Gay S, Scholmerich J, Muller-Ladner U. 2002. Inhibition of cartilage destruction by double gene transfer of IL-IRa and IL-10 involves the activin pathway. Gene Ther 9(22): 1508-1519.
97. Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM, Yeh ET. 1996. Protection against Fas/APO-1-and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157(10): 4277-4281.
98. Ospelt C, Neidhart M, Michel BA, Simmen B, Gay RE, Gay S. 2004. p38delta induces MMP-3 in activated rhuematoid arthritis synovial fibroblasts. Arthrit and Rheum 10(abstract) 50(9): S155.
99. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adama J, Grisham MB. 1998. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95(26): 15671-15676.
100. Pap T, Gay S, Schett G. 2003. Matrix Metalloproteinases. In: Smolen JS, Lipsky PE (eds). Martin Dunitz/Taylor & Francis: London, pp. 483-497
101. Pap T, Muller-Ladner U, Gay RE, Gay S. 2000a. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthrit Res 2(5): 361-367.
102. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. 2000b. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthrit Res 2(1): 59-64.
103. Pap T, Nawrath M, Heinrich J, Bosse M, Baier A, Hummel KM, Petrow P, Kuchen S, Michel BA, Gay RE, Muller-Ladner U, Moelling K, Gay S. 2004. Cooperation of Ras-and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthrit Rheum 50(9): 2794-2802.
104. Parks E, Strieter RM, Lukacs NW, Gauldie J, Hitt M, Graham FL, Kunkel SL. 1998. Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. J Immunol 160(9): 4615-4619.
105. Perlman H, Liu H, Georganas C, Koch AE, Shamiyeh E, Haines GK. 3rd, and Pope RM. 2001. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. Arthrit Rheum 44(12): 2899-2908.
106. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, Kyburz D. 2004. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 172(2): 1256-1265.
107. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y. 2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108(12): 1825-1832.
108. Plows D, Kontogeorgos G, Kollias G. 1999. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 162(2): 1018-1023.
109. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, Roshak AK. 2005. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of I{k}B kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmac Exp Ther 312(1): 373-381.
110. Qu Z, Garcia CH, O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT. 1994. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthrit Rheum 37(2): 212-220.
111. Ranges GE, Sriram S, Cooper SM. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 162(3): 1105-1110.
112. Rinaldi N, Schwarz-Eywill M, Weis D, Leppelmann-Jansen P, Lukoschek M, Keilholz U, Barth TF. 1997. Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 56(1): 45-51.
113. Romas E, Gillespie MT, Martin TJ. 2002. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30(2): 340-346.
114. Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC. 2002. Osteoprotegerin and inflammation. Eur Cytokine Netw 13(2): 144-153.
115. Schedel J, Gay RE, Kuenzler P, Seemayer C, Simmen B, Michel BA, Gay S. 2002. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthrit Rheum 46(6): 1512-1518.
116. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G. 2000. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogenactivated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthrit Rheum 43(11): 2501-2512.
117. Schulze-Koops H, Kalden JR. 2001. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 15(5): 677-691.
118. Schwartz MA. 1997. Integrins, oncogenes, and anchorage independence. J Cell Biol 139(3): 575-578.
119. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay S, Lauener RP. 2003. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 162(4): 1221-1227.
120. Smith JB, Haynes MK. 2002. Rheumatoid arthritis-a molecular understanding. Ann Intern Med 136(12): 908-922.
121. Stahl H, L, S, J, S, Filipowicz-Sosnowska A, Edwards JCW. 2003. Rituximamb in RA: efficacy and safety from a randomised controlled trial. Ann Rheum Dis 62(suppl 1): 65.
122. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. 1999. Selective accumulation of CCR5{thorn} T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 11(4): 553-559.
123. Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T. 2000. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha-or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett 465(1): 23-27.
124. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. 1997. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthrit Rheum 40(2): 217-225.
125. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. 2000. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthrit Rheum 43(2): 259-269.
126. Tanaka M, Harigai M, Kawaguchi Y, Ohta S, Sugiura T, Takagi K, Ohsako-Higami S, Fukasawa C, Hara M, Kamatani N. 2001. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol 28(8): 1779-1787.
127. Tarner IH, Fathman CG. 2001. Gene therapy in autoimmune disease. Curr Opin Immunol 13(6): 676-682.
128. Tarner IH, Muller-Ladner U, Gay RE, Fathman CG, Gay S. 2003. The pathogenesis of rheumatoid arthritis-gene transfer to detect novel targets for treatment. In: Zouli M (ed.). NATO Science Series: Life and Behavioural Sciences, IOS Press: Amsterdam, pp. 315-346
129. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. 2000. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthrit Rheum 43(1): 38-47.
130. Thomas R, McIlraith M, Davis LS, Lipsky PE. 1992. Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthrit Rheum 35(12): 1455-1465.
131. Tolar J, Teitelbaum SL, Orchard PJ. 2004. Osteopetrosis. New Engl J Med 351(27): 2839-2849.
132. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Fassbender HG, Gay S. 1992. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol Int 12(2): 53-59.
133. van de Loo FA, van den Berg WB. 2002. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin N Am 28(1): 127-149.
134. van den Berg WB, Bresnihan B. 1999. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Baillières Best Pract Res Clin Rheumatol 13(4): 577-597.
135. van den Berg WB, van de Loo FA, Otterness I, Arntz O, Joosten LA. 1991. In vivo evidence for a key role of IL-1 in cartilage destruction in experimental arthritis. Agents Actions Suppl 32: 159-163.
136. van der Laan WH, Pap T, Ronday HK, Grimbergen JM, Huisman LG, TeKoppele JM, Breedveld FC, Gay RE, Gay S, Huizinga TW, Verheijen JH, Quax PH. 2000. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthrit Rheum 43(8): 1710-1718.
137. van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T. 2003. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 10(3): 234-242.
138. Vincenti MP, Coon CI, Brinckerhoff CE. 1998. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthrit Rheum 41(11): 1987-1994.
139. Zinkernagel RM. 2001. Maternal antibodies, childhood infections, and autoimmune diseases. New Engl J Med 345(18): 1331-1335.
140. Zvaifler NJ, Boyle D, Firestein GS. 1994. Early synovitis-synoviocytes and mononuclear cells. Sem Arthritis Rheum 23(6 suppl 2): 11-16.
141. Zvaifler NJ, Tsai V, Alsalameh S, Von Kempis J, Firestein GS, Lotz M. 1997. Pannocytes: distinctive cells found in rheumatoid arthritis articular cartilage erosions. Am J Pathol 150(3): 1125-1138.